Genetic, genomic and epigenetic studies as tools for elucidating disease pathogenesis in primary Sjögren’s syndrome

References

• Fox RI, Pearson G, Vaughan JH. Detection of Epstein-Barr virus-associated antigens and DNA in salivary gland biopsies from patients with Sjogren’s syndrome. J Immunol 1986;137:3162-8
   PubMed Web of Science ®Google Scholar
• Mariette X, Gozlan J, Clerc D, et al. Detection of Epstein-Barr virus DNA by in situ hybridization and polymerase chain reaction in salivary gland biopsy specimens from patients with Sjogren’s syndrome. Am J Med 1991;90:286-94
   PubMed Web of Science ®Google Scholar
• Saito I, Servenius B, Compton T, Fox RI. Detection of Epstein-Barr virus DNA by polymerase chain reaction in blood and tissue biopsies from patients with Sjogren’s syndrome. J Exp Med 1989;169:2191-8
   PubMed Web of Science ®Google Scholar
• Chused TM, Kassan SS, Opelz G, et al. Sjogren’s syndrome association with HLA-Dw3. N Engl J Med 1977;296:895-7
   PubMed Web of Science ®Google Scholar
• Kang HI, Fei HM, Saito I, et al. Comparison of HLA class II genes in Caucasoid, Chinese, and Japanese patients with primary Sjogren’s syndrome. J Immunol 1993;150:3615-23
   PubMed Web of Science ®Google Scholar
• Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8
   PubMed Web of Science ®Google Scholar
• Rasmussen A, Ice JA, Li H, et al. Comparison of the American-European Consensus Group Sjogren’s syndrome classification criteria to newly proposed American College of Rheumatology criteria in a large, carefully characterised sicca cohort. Ann Rheum Dis 2014;73(1):31-8
   PubMed Web of Science ®Google Scholar
• Shiboski SC, Shiboski CH, Criswell L, et al. American College of Rheumatology classification criteria for Sjogren’s syndrome: a data-driven, expert consensus approach in the Sjogren’s International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) 2012;64:475-87
   PubMed Web of Science ®Google Scholar
• Gottenberg JE, Cagnard N, Lucchesi C, et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren’s syndrome. Proc Natl Acad Sci USA 2006;103:2770-5
   PubMed Web of Science ®Google Scholar
• Mavragani CP, Crow MK. Activation of the type I interferon pathway in primary Sjogren’s syndrome. J Autoimmun 2010;35:225-31
   PubMed Web of Science ®Google Scholar
• Emamian ES, Leon JM, Lessard CJ, et al. Peripheral blood gene expression profiling in Sjogren’s syndrome. Genes Immun 2009;10:285-96
   PubMed Web of Science ®Google Scholar
• Nishikomori R, Usui T, Wu CY, et al. Activated STAT4 has an essential role in Th1 differentiation and proliferation that is independent of its role in the maintenance of IL-12R beta 2 chain expression and signaling. J Immunol 2002;169:4388-98
   PubMed Web of Science ®Google Scholar
• O’Connell RM, Rao DS, Chaudhuri AA, Baltimore D. Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol 2010;10:111-22
   PubMed Web of Science ®Google Scholar
• Anaya JM, Tobon GJ, Vega P, Castiblanco J. Autoimmune disease aggregation in families with primary Sjogren’s syndrome. J Rheumatol 2006;33:2227-34
   PubMed Web of Science ®Google Scholar
• Anaya JM, Castiblanco J, Tobon GJ, et al. Familial clustering of autoimmune diseases in patients with type 1 diabetes mellitus. J Autoimmun 2006;26:208-14
   PubMed Web of Science ®Google Scholar
• Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 2001;411:599-603
   PubMed Web of Science ®Google Scholar
• Hugot JP, Laurent-Puig P, Gower-Rousseau C, et al. Mapping of a susceptibility locus for Crohn’s disease on chromosome 16. Nature 1996;379:821-3
   PubMed Web of Science ®Google Scholar
• Anaya JM, Delgado-Vega AM, Castiblanco J. Genetic basis of Sjogren’s syndrome. How strong is the evidence? Clin Dev Immunol 2006;13:209-22
   PubMedGoogle Scholar
• Nordmark G, Kristjansdottir G, Theander E, et al. Association of EBF1, FAM167A(C8orf13)-BLK and TNFSF4 gene variants with primary Sjogren’s syndrome. Genes Immun 2011;12:100-9
   PubMed Web of Science ®Google Scholar
• Richard-Miceli C, Criswell LA. Emerging patterns of genetic overlap across autoimmune disorders. Genome Med 2012;4:6
   PubMed Web of Science ®Google Scholar
• Lessard CJ, Li H, Adrianto I, et al. Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjogren’s syndrome. Nat Genet 2013;45(11):1284-92
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang K, Chen H, et al. A genome-wide association study in Han Chinese identifies a susceptibility locus for primary Sjogren’s syndrome at 7q11.23. Nat Genet 2013;45:1361-5
   PubMed Web of Science ®Google Scholar
• Cruz-Tapias P, Rojas-Villarraga A, Maier-Moore S, Anaya JM. HLA and Sjogren’s syndrome susceptibility. A meta-analysis of worldwide studies. Autoimmun Rev 2012;11:281-7
   PubMed Web of Science ®Google Scholar
• Sigurdsson S, Nordmark G, Goring HH, et al. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet 2005;76:528-37
   PubMed Web of Science ®Google Scholar
• Demirci FY, Manzi S, Ramsey-Goldman R, et al. Association of a common interferon regulatory factor 5 (IRF5) variant with increased risk of systemic lupus erythematosus (SLE). Ann Hum Genet 2007;71:308-11
   PubMed Web of Science ®Google Scholar
• Ferreiro-Neira I, Calaza M, Alonso-Perez E, et al. Opposed independent effects and epistasis in the complex association of IRF5 to SLE. Genes Immun 2007;8:429-38
   PubMed Web of Science ®Google Scholar
• Graham RR, Kyogoku C, Sigurdsson S, et al. Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci USA 2007;104:6758-63
   PubMed Web of Science ®Google Scholar
• Kelly JA, Kelley JM, Kaufman KM, et al. Interferon regulatory factor-5 is genetically associated with systemic lupus erythematosus in African Americans. Genes Immun 2008;9:187-94
   PubMed Web of Science ®Google Scholar
• Kozyrev SV, Alarcon-Riquelme ME. The genetics and biology of Irf5-mediated signaling in lupus. Autoimmunity 2007;40:591-601
   PubMed Web of Science ®Google Scholar
• Kozyrev SV, Lewen S, Reddy PM, et al. Structural insertion/deletion variation in IRF5 is associated with a risk haplotype and defines the precise IRF5 isoforms expressed in systemic lupus erythematosus. Arthritis Rheum 2007;56:1234-41
   PubMed Web of Science ®Google Scholar
• Reddy MV, Velazquez-Cruz R, Baca V, et al. Genetic association of IRF5 with SLE in Mexicans: higher frequency of the risk haplotype and its homozygosity than Europeans. Hum Genet 2007;121:721-7
   Google Scholar
• Shin HD, Sung YK, Choi CB, et al. Replication of the genetic effects of IFN regulatory factor 5 (IRF5) on systemic lupus erythematosus in a Korean population. Arthritis Res Ther 2007;9:R32
   PubMed Web of Science ®Google Scholar
• Siu HO, Yang W, Lau CS, et al. Association of a haplotype of IRF5 gene with systemic lupus erythematosus in Chinese. J Rheumatol 2008;35:360-2
   PubMed Web of Science ®Google Scholar
• Miceli-Richard C, Comets E, Loiseau P, et al. Association of an IRF5 gene functional polymorphism with Sjogren’s syndrome. Arthritis Rheum 2007;56:3989-94
   PubMed Web of Science ®Google Scholar
• Nordmark G, Kristjansdottir G, Theander E, et al. Additive effects of the major risk alleles of IRF5 and STAT4 in primary Sjogren’s syndrome. Genes Immun 2009;10:68-76
   PubMed Web of Science ®Google Scholar
• Dideberg V, Kristjansdottir G, Milani L, et al. An insertion-deletion polymorphism in the interferon regulatory Factor 5 (IRF5) gene confers risk of inflammatory bowel diseases. Hum Mol Genet 2007;16:3008-16
   PubMed Web of Science ®Google Scholar
• Kristjansdottir G, Sandling JK, Bonetti A, et al. Interferon regulatory factor 5 (IRF5) gene variants are associated with multiple sclerosis in three distinct populations. J Med Genet 2008;45(6):362-9
   PubMed Web of Science ®Google Scholar
• Wang C, Kokkonen H, Sandling JK, et al. Preferential association of interferon regulatory factor 5 gene variants with seronegative rheumatoid arthritis in 2 Swedish case-control studies. J Rheumatol 2011;38:2130-2
   PubMed Web of Science ®Google Scholar
• Miceli-Richard C, Gestermann N, Ittah M, et al. The CGGGG insertion/deletion polymorphism of the IRF5 promoter is a strong risk factor for primary Sjogren’s syndrome. Arthritis Rheum 2009;60:1991-7
   PubMed Web of Science ®Google Scholar
• Remmers EF, Plenge RM, Lee AT, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2007;357:977-86
   PubMed Web of Science ®Google Scholar
• Farrar JD, Smith JD, Murphy TL, Murphy KM. Recruitment of Stat4 to the human interferon-alpha/beta receptor requires activated Stat2. J Biol Chem 2000;275:2693-7
   PubMedGoogle Scholar
• Nguyen KB, Watford WT, Salomon R, et al. Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection. Science 2002;297:2063-6
   PubMed Web of Science ®Google Scholar
• Kariuki SN, Kirou KA, MacDermott EJ, et al. Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo. J Immunol 2009;182:34-8
   PubMed Web of Science ®Google Scholar
• Gestermann N, Mekinian A, Comets E, et al. STAT4 is a confirmed genetic risk factor for Sjogren’s syndrome and could be involved in type 1 interferon pathway signaling. Genes Immun 2010;11:432-8
   PubMed Web of Science ®Google Scholar
• Palomino-Morales RJ, Diaz-Gallo LM, Witte T, et al. Influence of STAT4 polymorphism in primary Sjogren’s syndrome. J Rheumatol 2010;37:1016-19
   PubMed Web of Science ®Google Scholar
• Abelson AK, Delgado-Vega AM, Kozyrev SV, et al. STAT4 associates with systemic lupus erythematosus through two independent effects that correlate with gene expression and act additively with IRF5 to increase risk. Ann Rheum Dis 2009;68:1746-53
   PubMed Web of Science ®Google Scholar
• Hom G, Graham RR, Modrek B, et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med 2008;358:900-9
   PubMed Web of Science ®Google Scholar
• Gourh P, Agarwal SK, Martin E, et al. Association of the C8orf13-BLK region with systemic sclerosis in North-American and European populations. J Autoimmun 2010;34:155-62
   PubMed Web of Science ®Google Scholar
• Genin E, Coustet B, Allanore Y, et al. Epistatic interaction between BANK1 and BLK in rheumatoid arthritis: results from a large trans-ethnic meta-analysis. PLoS ONE 2013;8:e61044
   PubMed Web of Science ®Google Scholar
• Boone DL, Turer EE, Lee EG, et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol 2004;5:1052-60
   PubMed Web of Science ®Google Scholar
• Wertz IE, O’Rourke KM, Zhou H, et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 2004;430:694-9
   PubMed Web of Science ®Google Scholar
• Heyninck K, Beyaert R. The cytokine-inducible zinc finger protein A20 inhibits IL-1-induced NF-kappaB activation at the level of TRAF6. FEBS Lett 1999;442:147-50
   PubMed Web of Science ®Google Scholar
• Lee EG, Boone DL, Chai S, et al. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 2000;289:2350-4
   PubMed Web of Science ®Google Scholar
• Turer EE, Tavares RM, Mortier E, et al. Homeostatic MyD88-dependent signals cause lethal inflamMation in the absence of A20. J Exp Med 2008;205:451-64
   PubMed Web of Science ®Google Scholar
• Oshima N, Ishihara S, Rumi MA, et al. A20 is an early responding negative regulator of Toll-like receptor 5 signalling in intestinal epithelial cells during inflammation. Clin Exp Immunol 2010;159(2):185-98
   PubMed Web of Science ®Google Scholar
• Plenge RM, Cotsapas C, Davies L, et al. Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat Genet 2007;39:1477-82
   PubMed Web of Science ®Google Scholar
• Bowes J, Lawrence R, Eyre S, et al. Rare variation at the TNFAIP3 locus and susceptibility to rheumatoid arthritis. Hum Genet 2010;128:627-33
   PubMed Web of Science ®Google Scholar
• Graham RR, Cotsapas C, Davies L, et al. Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nat Genet 2008;40:1059-61
   PubMed Web of Science ®Google Scholar
• Musone SL, Taylor KE, Lu TT, et al. Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat Genet 2008;40:1062-4
   PubMed Web of Science ®Google Scholar
• Ma A, Malynn BA. A20: linking a complex regulator of ubiquitylation to immunity and human disease. Nat Rev Immunol 2012;12:774-85
   PubMed Web of Science ®Google Scholar
• Musone SL, Taylor KE, Nititham J, et al. Sequencing of TNFAIP3 and association of variants with multiple autoimmune diseases. Genes Immun 2011;12:176-82
   PubMed Web of Science ®Google Scholar
• Kato M, Sanada M, Kato I, et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 2009;459:712-16
   PubMed Web of Science ®Google Scholar
• Novak U, Rinaldi A, Kwee I, et al. The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood 2009;113:4918-21
   PubMed Web of Science ®Google Scholar
• Schmitz R, Hansmann ML, Bohle V, et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med 2009;206:981-9
   PubMed Web of Science ®Google Scholar
• Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005;165:2337-44
   PubMed Web of Science ®Google Scholar
• Nocturne G, Boudaoud S, Miceli-Richard C, et al. Germline and somatic genetic variations of TNFAIP3 in lymphoma complicating primary Sjogren’s syndrome. Blood 2013;122(25):4068-76
   PubMed Web of Science ®Google Scholar
• Cunninghame Graham DS, Graham RR, et al. Polymorphism at the TNF superfamily gene TNFSF4 confers susceptibility to systemic lupus erythematosus. Nat Genet 2008;40:83-9
   PubMed Web of Science ®Google Scholar
• Gourh P, Arnett FC, Tan FK, et al. Association of TNFSF4 (OX40L) polymorphisms with susceptibility to systemic sclerosis. Ann Rheum Dis 2010;69:550-5
   PubMed Web of Science ®Google Scholar
• Achiron A, Feldman A, Mandel M, Gurevich M. Impaired expression of peripheral blood apoptotic-related gene transcripts in acute multiple sclerosis relapse. Ann N Y Acad Sci 2007;1107:155-67
   PubMed Web of Science ®Google Scholar
• Kaizer EC, Glaser CL, Chaussabel D, et al. Gene expression in peripheral blood mononuclear cells from children with diabetes. J Clin Endocrinol Metab 2007;92:3705-11
   PubMed Web of Science ®Google Scholar
• Peterson KS, Huang JF, Zhu J, et al. Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli. J Clin Invest 2004;113:1722-33
   PubMed Web of Science ®Google Scholar
• Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003;100:2610-15
   PubMed Web of Science ®Google Scholar
• Crow MK, Wohlgemuth J. Microarray analysis of gene expression in lupus. Arthritis Res Ther 2003;5:279-87
   PubMed Web of Science ®Google Scholar
• Han GM, Chen SL, Shen N, et al. Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. Genes Immun 2003;4:177-86
   PubMed Web of Science ®Google Scholar
• Bave U, Nordmark G, Lovgren T, et al. Activation of the type I interferon system in primary Sjogren’s syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 2005;52:1185-95
   PubMed Web of Science ®Google Scholar
• Hjelmervik TO, Petersen K, Jonassen I, et al. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjogren’s syndrome patients from healthy control subjects. Arthritis Rheum 2005;52:1534-44
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97
   PubMed Web of Science ®Google Scholar
• Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 2006;103:12481-6
   PubMed Web of Science ®Google Scholar
• Stagakis E, Bertsias G, Verginis P, et al. Identification of novel microRNA signatures linked to human lupus disease activity and pathogenesis: miR-21 regulates aberrant T cell responses through regulation of PDCD4 expression. Ann Rheum Dis 2011;70(8):1496-506
   PubMed Web of Science ®Google Scholar
• Tang Y, Luo X, Cui H, et al. MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum 2009;60:1065-75
   PubMed Web of Science ®Google Scholar
• Sonkoly E, Wei T, Janson PC, et al. MicroRNAs: novel regulators involved in the pathogenesis of psoriasis? PLoS One 2007;2:e610
   PubMed Web of Science ®Google Scholar
• Nakasa T, Shibuya H, Nagata Y, et al. The inhibitory effect of microRNA-146a expression on bone destruction in collagen-induced arthritis. Arthritis Rheum 2011;63:1582-90
   PubMed Web of Science ®Google Scholar
• Pauley KM, Stewart CM, Gauna AE, et al. Altered miR-146a expression in Sjogren’s syndrome and its functional role in innate immunity. Eur J Immunol 2011;41:2029-39
   PubMed Web of Science ®Google Scholar
• Alevizos I, Alexander S, Turner RJ, Illei GG. MicroRNA expression profiles as biomarkers of minor salivary gland inflammation and dysfunction in Sjogren’s syndrome. Arthritis Rheum 2011;63:535-44
   PubMed Web of Science ®Google Scholar
• Lu Q, Wu A, Tesmer L, et al. Demethylation of CD40LG on the inactive X in T cells from women with lupus. J Immunol 2007;179:6352-8
   PubMed Web of Science ®Google Scholar
• Lieberman MW, Beach LR, Palmiter RD. Ultraviolet radiation-induced metallothionein-I gene activation is associated with extensive DNA demethylation. Cell 1983;35:207-14
   PubMed Web of Science ®Google Scholar
• Cornacchia E, Golbus J, Maybaum J, et al. Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J Immunol 1988;140:2197-200
   PubMed Web of Science ®Google Scholar
• Belkhir R, Gestermann N, Koutero M, et al. Upregulation of membrane-bound CD40L on CD4+ T cells in women with primary Sjogren’s syndrome. Scand J Immunol 2014;79:37-42
   PubMed Web of Science ®Google Scholar
• Gestermann N, Koutero M, Belkhir R, et al. Methylation profile of the promoter region of IRF5 in primary Sjogren’s syndrome. Eur Cytokine Netw 2013;23:166-72
   Web of Science ®Google Scholar
• Altorok N, Coit P, Hughes T, et al. Genome-wide DNA methylation patterns in naive CD4+ T cells from patients with primary Sjogren’s syndrome. Arthritis Rheumatol 2014;66:731-9
   PubMed Web of Science ®Google Scholar